Molnupiravir, the antiviral drug was initially developed for the treatment of influenza and is repurposed to completely suppress the COVID virus transmission within 24 hours.... Jun 11
A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration... Sep 23
Hyderabad's Avra Labs to make Favipiravir for Cipla's Ciplenza ... Jul 28
Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19... Jul 27
Cipla and Brinton Pharmaceutical's cheap Favipiravir to hit the market soon... Jul 24
Pune based Brinton Pharmaceutical gets DGCI nod for Favipiravir... Jul 24
India lockdown was it effective ? And how India is gearing up for vaccines read on to understand the recent scenarios... May 01
-Advertisements-